JP2011516070A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011516070A5 JP2011516070A5 JP2011503242A JP2011503242A JP2011516070A5 JP 2011516070 A5 JP2011516070 A5 JP 2011516070A5 JP 2011503242 A JP2011503242 A JP 2011503242A JP 2011503242 A JP2011503242 A JP 2011503242A JP 2011516070 A5 JP2011516070 A5 JP 2011516070A5
- Authority
- JP
- Japan
- Prior art keywords
- common
- protein
- chikv
- immunogenic
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 50
- 230000002163 immunogen Effects 0.000 claims description 31
- 108090000565 Capsid Proteins Proteins 0.000 claims description 11
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 11
- 101710125507 Integrase/recombinase Proteins 0.000 claims description 10
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 claims description 10
- 210000000234 capsid Anatomy 0.000 claims description 10
- 230000028993 immune response Effects 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims 49
- 239000012634 fragment Substances 0.000 claims 30
- 239000000203 mixture Substances 0.000 claims 24
- 102000039446 nucleic acids Human genes 0.000 claims 19
- 108020004707 nucleic acids Proteins 0.000 claims 19
- 150000007523 nucleic acids Chemical class 0.000 claims 19
- 108010008038 Synthetic Vaccines Proteins 0.000 claims 5
- 229940124551 recombinant vaccine Drugs 0.000 claims 5
- 102100034353 Integrase Human genes 0.000 claims 4
- 108010078428 env Gene Products Proteins 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000001939 inductive effect Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 238000004520 electroporation Methods 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 241001502567 Chikungunya virus Species 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4266108P | 2008-04-04 | 2008-04-04 | |
| US61/042,661 | 2008-04-04 | ||
| PCT/US2009/039656 WO2009124312A2 (en) | 2008-04-04 | 2009-04-06 | Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015011205A Division JP2015083017A (ja) | 2008-04-04 | 2015-01-23 | チクングニヤウィルスタンパク質の共通配列、これをコードする核酸分子、並びにこれを使用する組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011516070A JP2011516070A (ja) | 2011-05-26 |
| JP2011516070A5 true JP2011516070A5 (enExample) | 2012-07-05 |
| JP5744719B2 JP5744719B2 (ja) | 2015-07-08 |
Family
ID=41136129
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011503242A Expired - Fee Related JP5744719B2 (ja) | 2008-04-04 | 2009-04-06 | チクングニヤウィルスタンパク質の共通配列、これをコードする核酸分子、並びにこれを使用する組成物および方法 |
| JP2015011205A Pending JP2015083017A (ja) | 2008-04-04 | 2015-01-23 | チクングニヤウィルスタンパク質の共通配列、これをコードする核酸分子、並びにこれを使用する組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015011205A Pending JP2015083017A (ja) | 2008-04-04 | 2015-01-23 | チクングニヤウィルスタンパク質の共通配列、これをコードする核酸分子、並びにこれを使用する組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8852609B2 (enExample) |
| EP (1) | EP2274442B1 (enExample) |
| JP (2) | JP5744719B2 (enExample) |
| KR (1) | KR101589511B1 (enExample) |
| CN (2) | CN107083391A (enExample) |
| AU (1) | AU2009231559B2 (enExample) |
| CA (1) | CA2720166A1 (enExample) |
| ES (1) | ES2588738T3 (enExample) |
| WO (1) | WO2009124312A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010071610A1 (en) * | 2008-12-19 | 2010-06-24 | Agency For Science, Technology And Research (A*Star) | Severe chikungunya biomarkers |
| EP2374816B1 (en) * | 2010-04-07 | 2016-09-28 | Agency For Science, Technology And Research | Binding molecules against Chikungunya virus and uses thereof |
| US9441032B2 (en) | 2010-04-07 | 2016-09-13 | Agency For Science, Technology And Research | Binding molecules against Chikungunya virus and uses thereof |
| KR101939150B1 (ko) | 2010-11-12 | 2019-01-17 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 공통 전립선 항원, 이것을 암호화하는 핵산 분자, 그리고 이것을 포함하는 백신 및 용도 |
| WO2012078116A1 (en) * | 2010-12-10 | 2012-06-14 | Agency For Science, Technology And Research | Immunogenic chikungunya virus peptides |
| ES2806263T3 (es) | 2011-02-11 | 2021-02-17 | Univ Pennsylvania | Molécula de ácido nucleico que codifica la proteína del núcleo del virus de la hepatitis b y vacuna que comprende la misma |
| JP6567824B2 (ja) * | 2011-10-12 | 2019-08-28 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ヒトパピローマウイルスのワクチンおよびその使用方法 |
| EP2712871A1 (en) * | 2012-09-27 | 2014-04-02 | Institut Pasteur | Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications |
| KR20230156146A (ko) | 2012-12-13 | 2023-11-13 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Dna 항체 작제물 및 그 이용 방법 |
| US10232030B2 (en) | 2013-03-12 | 2019-03-19 | Inovio Pharmaceuticals, Inc. | Vaccines for human papilloma virus and methods for using the same |
| EP2968448A4 (en) | 2013-03-15 | 2016-02-17 | Univ Pennsylvania | COMPOSITIONS USING HYPOXY-INDUCIBLE FACTOR 1-ALPHA AND METHOD OF USE THEREOF |
| EP3021868A4 (en) | 2013-07-19 | 2017-03-01 | Integral Molecular, Inc. | Antibodies against chikungunya virus and uses thereof |
| EP3226892A4 (en) | 2014-12-01 | 2018-07-18 | The Trustees Of The University Of Pennsylvania | Dna antibody constructs and method of using same |
| JP2019509350A (ja) * | 2016-03-21 | 2019-04-04 | ビー.ウェイナー デイビッド | Dna抗体構築物及びその使用方法 |
| US11286295B2 (en) | 2016-10-20 | 2022-03-29 | Sanofi | Anti-CHIKV monoclonal antibodies directed against the E2 structural protein |
| JP6795468B2 (ja) * | 2017-07-14 | 2020-12-02 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ヒトパピローマウイルスのワクチンおよびその使用方法 |
| US11484587B2 (en) * | 2017-09-21 | 2022-11-01 | Valneva Se | Method of producing pharmaceutical compositions comprising immunogenic Chikungunya virus CHIKV-Delta5nsP3 |
| WO2019148086A1 (en) * | 2018-01-26 | 2019-08-01 | The Wistar Institute Of Anatomy And Biology | Vaccines against mosquito-borne viruses, and methods of using same |
| CN109536464B (zh) * | 2018-12-10 | 2022-06-10 | 中国科学院武汉病毒研究所 | 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用 |
| BR112021014255A2 (pt) * | 2019-01-30 | 2022-01-18 | Wistar Inst | Molécula de ácido nucleico, composição, e, método de prevenção ou tratamento de uma doença ou distúrbio |
| KR102202082B1 (ko) | 2019-09-25 | 2021-01-11 | 충북대학교 산학협력단 | 치쿤군야 바이러스의 외피단백질 도메인 ⅱ에 대해 특이적으로 결합하는 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도 |
| JP7075130B2 (ja) * | 2019-10-25 | 2022-05-25 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ヒトパピローマウイルスのワクチンおよびその使用方法 |
| KR102864666B1 (ko) | 2025-04-21 | 2025-09-29 | 대한민국 | 치쿤구니아 바이러스 외피 재조합 dna를 포함하는 백신 조성물 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5077044A (en) | 1980-05-19 | 1991-12-31 | The Board Of Trustees Of The Leland Stanford Jr. University | Novel non-reverting shigella live vaccines |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
| US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
| US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
| US5223424A (en) | 1985-09-06 | 1993-06-29 | Prutech Research And Development | Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence |
| US5310668A (en) | 1986-06-20 | 1994-05-10 | Merck & Co., Inc. | Varicella-zoster virus as a live recombinant vaccine |
| US5242829A (en) | 1986-09-23 | 1993-09-07 | Therion Biologics Corporation | Recombinant pseudorabies virus |
| US5294441A (en) | 1987-06-04 | 1994-03-15 | Washington University | Avirulent microbes and uses therefor: salmonella typhi |
| US5387744A (en) | 1987-06-04 | 1995-02-07 | Washington University | Avirulent microbes and uses therefor: Salmonella typhi |
| IL86583A0 (en) | 1987-06-04 | 1988-11-15 | Molecular Eng Ass | Vaccine containing a derivative of a microbe and method for the production thereof |
| US5112749A (en) | 1987-10-02 | 1992-05-12 | Praxis Biologics, Inc. | Vaccines for the malaria circumsporozoite protein |
| US5225336A (en) | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
| CH682669A5 (fr) | 1989-03-08 | 1993-10-29 | Health Research Inc | Virus recombinant modifié pour exprimer un produit de gènes chez un hôte, procédés et vaccin correspondants. |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| JP3004049B2 (ja) | 1989-03-31 | 2000-01-31 | ワシントン ユニバーシティー | 病原性のないphoP型微生物を含有するワクチン |
| DE69016956T2 (de) | 1989-12-04 | 1995-07-20 | Akzo Nobel Nv | Rekombinantes Truthahn-Herpesvirus und davon abgeleiteter Lebendimpfstoffvektor. |
| US5294548A (en) | 1990-04-02 | 1994-03-15 | American Biogenetic Sciences, Inc | Recombianant Hepatitis a virus |
| US5462734A (en) | 1990-11-02 | 1995-10-31 | Wisconsin Alumni Research Foundation | Bovine herpesvirus vaccine and method of using same |
| US5240703A (en) | 1991-03-01 | 1993-08-31 | Syntro Corporation | Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof |
| US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
| US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| US5993434A (en) | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
| US5702359A (en) | 1995-06-06 | 1997-12-30 | Genetronics, Inc. | Needle electrodes for mediated delivery of drugs and genes |
| US5439440A (en) | 1993-04-01 | 1995-08-08 | Genetronics, Inc. | Electroporation system with voltage control feedback for clinical applications |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| NL9401820A (nl) | 1994-11-02 | 1996-06-03 | Meyn Maschf | Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte. |
| US5962428A (en) | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5810762A (en) | 1995-04-10 | 1998-09-22 | Genetronics, Inc. | Electroporation system with voltage control feedback for clinical applications |
| CA2285056C (en) | 1997-04-03 | 2004-12-14 | Iacob Mathiesen | Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle |
| US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| US6241701B1 (en) | 1997-08-01 | 2001-06-05 | Genetronics, Inc. | Apparatus for electroporation mediated delivery of drugs and genes |
| US6055453A (en) | 1997-08-01 | 2000-04-25 | Genetronics, Inc. | Apparatus for addressing needle array electrodes for electroporation therapy |
| US6216034B1 (en) | 1997-08-01 | 2001-04-10 | Genetronics, Inc. | Method of programming an array of needle electrodes for electroporation therapy of tissue |
| US6778853B1 (en) | 1997-12-17 | 2004-08-17 | University Of South Florida | Electroporation device |
| US6135990A (en) | 1997-12-17 | 2000-10-24 | University Of South Florida | Electroporation device and method |
| US6120493A (en) | 1998-01-27 | 2000-09-19 | Genetronics, Inc. | Method for the introduction of therapeutic agents utilizing an electroporation apparatus |
| AU3973599A (en) | 1998-05-08 | 1999-11-29 | Genetronics, Inc. | Electrically induced vessel vasodilation |
| US6678556B1 (en) | 1998-07-13 | 2004-01-13 | Genetronics, Inc. | Electrical field therapy with reduced histopathological change in muscle |
| US6697669B2 (en) | 1998-07-13 | 2004-02-24 | Genetronics, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
| AU2002211490A1 (en) * | 2000-10-04 | 2002-04-15 | The Trustees Of The University Of Pennsylvania | Compositions and methods of using capsid protein from flaviviruses and pestiviruses |
| EP1457211A4 (en) * | 2001-11-20 | 2006-06-14 | Japan Science & Tech Agency | VACCINE AGAINST RECOMBINANT VACCINE VIRUS |
| US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
| US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
| DK2290054T3 (en) * | 2002-12-13 | 2017-07-03 | Alphavax Inc | Alpha virus particles and processes for their preparation |
| AU2004249191B2 (en) | 2003-06-13 | 2011-01-06 | The Trustees Of The University Of Pennsylvania | Vaccines, immunotherapeutics and methods for using the same |
| NZ570709A (en) | 2003-06-13 | 2010-04-30 | Univ Pennsylvania | Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same |
| CA2545597A1 (en) * | 2006-03-15 | 2007-09-15 | Institut Pasteur | Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof |
| EP2073839B1 (en) * | 2006-09-01 | 2016-10-19 | Bharat Biotech International Limited | A vaccine for chikungunya virus infection |
| US9452285B2 (en) | 2006-10-17 | 2016-09-27 | Vgx Pharmaceuticals, Inc. | Electroporation devices and methods of using same for electroporation of cells in mammals |
| CN107574156A (zh) * | 2008-11-26 | 2018-01-12 | 美国国有健康与人类服务部 | 类病毒组合物颗粒及其使用方法 |
-
2009
- 2009-04-06 EP EP09727698.4A patent/EP2274442B1/en not_active Not-in-force
- 2009-04-06 WO PCT/US2009/039656 patent/WO2009124312A2/en not_active Ceased
- 2009-04-06 CN CN201611044710.XA patent/CN107083391A/zh active Pending
- 2009-04-06 AU AU2009231559A patent/AU2009231559B2/en not_active Ceased
- 2009-04-06 KR KR1020107024734A patent/KR101589511B1/ko not_active Expired - Fee Related
- 2009-04-06 ES ES09727698.4T patent/ES2588738T3/es active Active
- 2009-04-06 CA CA2720166A patent/CA2720166A1/en not_active Abandoned
- 2009-04-06 US US12/936,186 patent/US8852609B2/en active Active
- 2009-04-06 JP JP2011503242A patent/JP5744719B2/ja not_active Expired - Fee Related
- 2009-04-06 CN CN2009801128936A patent/CN101990580A/zh active Pending
-
2015
- 2015-01-23 JP JP2015011205A patent/JP2015083017A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011516070A5 (enExample) | ||
| US20240408195A1 (en) | Epstein-barr virus vaccines | |
| DK2988780T3 (en) | STABILIZED SOLVEN RSV-F PREFUSION POLYPTIDES | |
| CN111218459A (zh) | 一种以人复制缺陷腺病毒为载体的重组新型冠状病毒疫苗 | |
| CA3176527A1 (en) | Betacoronavirus prophylaxis and therapy | |
| WO2022077593A1 (zh) | 一种SARS-CoV-2冠状病毒疫苗及其制备方法 | |
| MD3439672T2 (ro) | Proteine F RVS de pre-fuziune solubile stabilizate pentru utilizare în profilixia infecţiilor cu RSV | |
| EP1054683A4 (en) | MODIFIED HEAT SHOCK PROTEIN / PEPTIDEANT COMPLEX | |
| KR101919002B1 (ko) | 구제역 바이러스의 가용성 다가 항원단백질 및 이의 용도 | |
| US20230190923A1 (en) | Compositions comprising ltb and pathogenic antigens, and use thereof | |
| Dalvie et al. | Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters | |
| EP3134117A1 (en) | Human cytomegalovirus vaccine compositions and method of producing the same | |
| DK1893228T3 (en) | CHIMERIC POLYPEPTIDES AND THEIR THERAPEUTIC APPLICATIONS TOWARDS A Flaviviridae INFECTION | |
| US20230233670A1 (en) | A Recombinant Modified Vaccinia Virus (MVA) Vaccine Against Coronavirus Disease | |
| CN104292338A (zh) | 含sars病毒n抗原的重组蛋白及展示n蛋白的杆状病毒 | |
| Shen et al. | DNA vaccine prime and replicating vaccinia vaccine boost induce robust humoral and cellular immune responses against MERS-CoV in mice | |
| CN105238767A (zh) | 人3型腺病毒展示人55型腺病毒中和抗原表位疫苗候选株的制备方法和应用 | |
| Huang et al. | Nipah virus attachment glycoprotein ectodomain delivered by type 5 adenovirus vector elicits broad immune response against NiV and HeV | |
| Choi et al. | Long-term egg-yolk adaptation of the Orientia tsutsugamushi for preparation of a formalinized immunogen | |
| JP2008500802A5 (enExample) | ||
| CN116731192A (zh) | 重组刺突蛋白及其制备方法和用途 | |
| Perdiguero et al. | B and T Cell Bi-Cistronic Multiepitopic Vaccine Induces Broad Immunogenicity and Provides Protection Against SARS-CoV-2 | |
| CN118561967A (zh) | 一种新型冠状病毒重组亚单位抗原及其制备方法和应用 | |
| CN118460619A (zh) | 无外源基序甲型流感病毒h1柄部三聚体蛋白及其应用 | |
| CN118638195A (zh) | 一种新型冠状病毒长多肽抗原及其应用 |